TGF-β binding antibodies
US7494651B2 · kind B2 · utility
17Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2006 |
| Grant date | Feb 24, 2009 |
| Priority date | — |
| Expiry date | Dec 20, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.